GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the first quarter ended March 31, 2026, and provided a business update highlighting continued advancement of its lead vaccine candidate GEO-MVA for mpox and smallpox, alongside strategic progress in its immuno-oncology initiatives centered on Gedeptin.
During the quarter and subsequent period, GeoVax continued operational execution activities supporting initiation of the planned Phase 3 immunobridging clinical study for GEO-MVA under an expedited regulatory pathway aligned with guidance from the European Medicines Agency (EMA). The company believes this pathway positions GEO-MVA for a potentially accelerated route toward regulatory authorization and commercialization as an additional source of MVA-based orthopoxvirus vaccine supply.
“GeoVax has strategically aligned the organization around GEO-MVA and the significant global opportunity for a diversified MVA vaccine supply,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “Our efforts are now centered on operational execution of the Phase 3 immunobridging program, supported by completed manufacturing activities, CRO selection, regulatory alignment, and advancing clinical trial initiation.”
Dodd continued, “We believe GEO-MVA is uniquely positioned at the intersection of global public health preparedness, biodefense resiliency, and domestic manufacturing priorities. The ongoing evolution of mpox, continued global supply constraints, and dependence on a single foreign supplier for MVA-based orthopoxvirus vaccines reinforce the importance of establishing additional scalable supply sources.”
The planned Phase 3 immunobridging study is expected to enroll approximately 500 participants and will evaluate neutralizing antibody responses relative to an approved MVA comparator vaccine. The study design is intended to provide rapid clinical validation through established immunobridging endpoints. Additionally, GeoVax has completed and released cGMP clinical trial material and fill/finish product for clinical use, and continues to advance continuous cell-line manufacturing initiatives utilizing the AGE1 platform to support future scalable MVA vaccine manufacturing capacity.
In its immuno-oncology segment, GeoVax continues advancing Gedeptin, its gene-directed enzyme prodrug therapy (GDEPT) platform, including planned combination strategies involving immune checkpoint inhibitors in head and neck cancer. The company recently strengthened its immuno-oncology positioning through an exclusive license agreement with Emory University covering intellectual property related to Gedeptin in combination with immune checkpoint inhibitors. GeoVax believes Gedeptin’s localized tumor-targeting and immune-activating mechanism may be complementary to PD-1-based therapies by helping convert immunologically “cold” tumors into more responsive tumor microenvironments.
For the first quarter of 2026, GeoVax reported a net loss of $5.3 million, compared to $5.4 million for the same period in 2025. Revenue from government contracts was zero in Q1 2026, versus $1.6 million in Q1 2025, which was associated with the BARDA/RRPV Project NextGen award for its GEO-CM04S1 COVID-19 vaccine program. That contract was terminated by BARDA in April 2025. Research and development expenses decreased to $3.9 million from $5.4 million, primarily due to lower costs from discontinued BARDA activities. General and administrative expenses declined to $1.4 million from $1.7 million. Cash and cash equivalents stood at $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025.
GeoVax’s strategic prioritization remains on GEO-MVA, reflecting established MVA platform validation, expedited regulatory alignment, large existing and anticipated orthopoxvirus vaccine demand, and growing interest in diversified vaccine supply chains and biodefense preparedness. The company also believes its immuno-oncology strategy centered on Gedeptin may provide meaningful long-term optionality within the rapidly evolving checkpoint inhibitor and combination immunotherapy landscape.
